Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes

被引:22
作者
Lebdai, Souhil [1 ]
Bigot, Pierre [1 ]
Leroux, Pierre-Adrien [1 ]
Berthelot, Louis-Paul [1 ]
Maulaz, Pierre [1 ]
Azzouzi, Abdel-Rahmene [1 ]
机构
[1] Univ Hosp Angers, Dept Urol, Angers, France
关键词
prostatic neoplasms; photochemotherapy; WST11; compound; therapeutic occlusion; treatment outcome; WST11; MODEL; TOOKAD((R)); ABLATION; EFFICACY; SAFETY;
D O I
10.1016/j.juro.2017.03.119
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We assessed the midterm oncologic outcomes of vascular targeted photodynamic therapy with padeliporfin for low risk prostate cancer treatment. Materials and Methods: We prospectively assessed all patients treated with vascular targeted photodynamic therapy for low risk prostate cancer at our center. Patients were followed every 6 months. All patients underwent prostate biopsies 6 months after treatment or when there was biological or clinical progression. The primary end point was progression-free survival. Secondary end points were absent clinically significant cancer in the treated lobes, radical therapy and the prostate specific antigen rate. Variables were compared with the chi-square, Mann-Whitney or Wilcoxon test. Progression-free survival is reported with Kaplan-Meier curves. Results: A total of 82 men were treated with vascular targeted photodynamic therapy. Median followup was 68 months (range 6 to 89). Median progressionfree survival was 86 months (95% CI 82-90). Median prostate specific antigen decreased significantly by 41% 6 months after treatment and it remained stable during followup (p < 0.001). A total of 115 lobes were treated and absent clinically significant cancer was achieved in 94 (82%). Of the 82 patients 20 (24%) underwent radical therapy, including radical prostatectomy in 18 and brachytherapy in 2, at a median of 22 months (range 6 to 86). Study limitations include a single arm design, small population size and midterm followup. Conclusions: Padeliporfin vascular targeted photodynamic therapy for low risk prostate cancer achieved an 82% rate of absent clinically significant cancer in treated lobes and 76% of patients avoided radical therapy at a median followup of 68 months. However, longer followup is required to determine long-term outcomes.
引用
收藏
页码:335 / 343
页数:9
相关论文
共 18 条
  • [1] TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer
    Azzouzi, A. R.
    Barret, E.
    Bennet, J.
    Moore, C.
    Taneja, S.
    Muir, G.
    Villers, A.
    Coleman, J.
    Allen, C.
    Scherz, A.
    Emberton, M.
    [J]. WORLD JOURNAL OF UROLOGY, 2015, 33 (07) : 945 - 953
  • [2] Padeliporfi n vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial
    Azzouzi, Abdel-Rahmene
    Vincendeau, Sebastien
    Barret, Eric
    Cicco, Antony
    Kleinclauss, Francois
    van der Poel, Henk G.
    Stief, Christian G.
    Rassweiler, Jens
    Salomon, Georg
    Solsona, Eduardo
    Alcaraz, Antonio
    Tammela, Teuvo T.
    Rosario, Derek J.
    Gomez-Veiga, Francisco
    Ahlgren, Goran
    Benzaghou, Fawzi
    Gaillac, Bertrand
    Amzal, Billy
    Debruyne, Frans M. J.
    Fromont, Gaelle
    Gratzke, Christian
    Emberton, Mark
    [J]. LANCET ONCOLOGY, 2017, 18 (02) : 181 - 191
  • [3] Vascular-targeted photodynamic therapy with TOOKADA® Soluble in localized prostate cancer: standardization of the procedure
    Azzouzi, Abdel-Rahmene
    Lebdai, Souhil
    Benzaghou, Fawzi
    Stief, Christian
    [J]. WORLD JOURNAL OF UROLOGY, 2015, 33 (07) : 937 - 944
  • [4] TOOKAD® Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer
    Azzouzi, Abdel-Rahmene
    Barret, Eric
    Moore, Caroline M.
    Villers, Arnaud
    Allen, Clare
    Scherz, Avigdor
    Muir, Gordon
    de Wildt, Michel
    Barber, Neil J.
    Lebdai, Souhil
    Emberton, Mark
    [J]. BJU INTERNATIONAL, 2013, 112 (06) : 766 - 774
  • [5] A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11
    Betrouni, Nacim
    Lopes, Renaud
    Puech, Philippe
    Colin, Pierre
    Mordon, Serge
    [J]. PHYSICS IN MEDICINE AND BIOLOGY, 2011, 56 (15) : 4771 - 4783
  • [6] Selectivity of the photosensitiser Tookad® for photodynamic therapy evaluated in the Syrian golden hamster cheek pouch tumour model
    Borle, F
    Radu, A
    Fontolliet, C
    van den Bergh, H
    Monnier, P
    Wagnières, G
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (12) : 2320 - 2326
  • [7] Novel water-soluble bacteriochlorophyll derivatives for vascular-targeted photodynamic therapy: Synthesis, solubility, phototoxicity and the effect of serum proteins
    Brandis, A
    Mazor, O
    Neumark, E
    Rosenbach-Belkin, V
    Salomon, Y
    Scherz, A
    [J]. PHOTOCHEMISTRY AND PHOTOBIOLOGY, 2005, 81 (04) : 983 - 993
  • [8] Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes
    Feijoo, Ernesto R. Cordeiro
    Sivaraman, Arjun
    Barret, Eric
    Sanchez-Salas, Rafael
    Galiano, Marc
    Rozet, Francois
    Prapotnich, Dominique
    Cathala, Nathalie
    Mombet, Annick
    Cathelineau, Xavier
    [J]. EUROPEAN UROLOGY, 2016, 69 (02) : 214 - 220
  • [9] EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent-Update 2013
    Heidenreich, Axel
    Bastian, Patrick J.
    Bellmunt, Joaquim
    Bolla, Michel
    Joniau, Steven
    van der Kwast, Theodor
    Mason, Malcolm
    Matveev, Vsevolod
    Wiegel, Thomas
    Zattoni, F.
    Mottet, Nicolas
    [J]. EUROPEAN UROLOGY, 2014, 65 (01) : 124 - 137
  • [10] Photodynamic therapy with Pd-bacteriopheophorbide (TOOKAD):: Successful in vivo treatment of human prostatic small cell carcinoma xenografts
    Koudinova, NV
    Pinthus, JH
    Brandis, A
    Brenner, O
    Bendel, P
    Ramon, J
    Eshhar, Z
    Scherz, A
    Salomon, Y
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (06) : 782 - 789